Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?
Sign Up to like & getrecommendations! Published in 2019 at "Neurotherapeutics"
DOI: 10.1007/s13311-019-00715-6
Abstract: Disease-modifying anti-rheumatic drugs (DMARDs) can reduce inflammation and slow progression of rheumatoid arthritis (RA). It remains unknown what impact DMARDs may have on dementia, where inflammation also plays a critical role in pathogenesis. Patients without… read more here.
Keywords: modifying anti; anti rheumatic; risk; disease modifying ... See more keywords
The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.105216
Abstract: Whether the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) would influence the risk of new-onset diabetes remains uncertain. Therefore, we performed a systematic review and meta-analysis to evaluate the association between the use of bDMARDs… read more here.
Keywords: incidence; modifying anti; anti rheumatic; incidence diabetes ... See more keywords
Initiating disease-modifying anti-rheumatic drugs rapidly reduces purchases of analgesic drugs in juvenile idiopathic arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Scandinavian Journal of Rheumatology"
DOI: 10.1080/03009742.2020.1762923
Abstract: Objective: To describe the use of analgesics 12 months before and after initiation of the first disease-modifying anti-rheumatic drug (DMARD) in children with juvenile idiopathic arthritis (JIA). Method: A register-based study linked three nationwide registers… read more here.
Keywords: modifying anti; juvenile idiopathic; anti rheumatic; index ... See more keywords
The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2019.1571498
Abstract: Abstract Aims: To estimate real world healthcare costs and resource utilization of rheumatoid arthritis (RA) patients associated with targeted disease modifying anti-rheumatic drugs (tDMARD) switching in general and switching to abatacept specifically. Materials and methods:… read more here.
Keywords: modifying anti; anti rheumatic; targeted disease; arthritis patients ... See more keywords
Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1483331
Abstract: ABSTRACT Introduction: Rheumatoid arthritis (RA) is associated with a heightened risk of cardiovascular disease (CVD), with both traditional CV risk factors and inflammation contributing to this risk. Areas covered: This review highlights the burden of… read more here.
Keywords: modifying anti; risk; risk factors; disease modifying ... See more keywords
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2348575
Abstract: ABSTRACT Introduction Disease-modifying anti-rheumatic drugs (DMARDs) have improved the outcomes of patients with rheumatoid arthritis (RA). DMARDs are classified into three categories: conventional synthetic DMARDs, biological DMARDs (including biosimilars), and targeted synthetic DMARDs. DMARDs, by… read more here.
Keywords: disease; rheumatic drugs; modifying anti; disease modifying ... See more keywords
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2024.2327589
Abstract: ABSTRACT Introduction The advent of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed the management of immune-mediated rheumatic diseases, including spondylarthritis (SpA). However, the data about combining b/ts DMARDs in the treatment of… read more here.
Keywords: synthetic disease; treatment; combination; modifying anti ... See more keywords
E075 Predictive factors for successful biologic disease-modifying anti-rheumatic drugs dose tapering in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.324
Abstract: Use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) have revolutionised the management of rheumatoid arthritis (RA). However, their use is not without side effects including infection and malignancy risk. Recent EULAR and ACR guidelines support consideration… read more here.
Keywords: dose tapering; anti rheumatic; biologic disease; rheumatoid ... See more keywords
Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti‐rheumatic agents for the treatment of psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.12685
Abstract: In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti‐tumor necrosis factor (anti‐TNF) in PsA; however cost remains a limiting factor. Non‐biologic disease modifying… read more here.
Keywords: modifying anti; psoriatic arthritis; anti rheumatic; disease modifying ... See more keywords
Consensus development on eligibility of government subsidisation of biologic disease modifying anti‐rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.12707
Abstract: The beneficial effects of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs), such as tumour necrosis factor inhibitors (anti‐TNF) in active ankylosing spondylitis (AS) are well established. The significant costs on patients in the absence of financial subsidization… read more here.
Keywords: modifying anti; anti rheumatic; ankylosing spondylitis; consensus development ... See more keywords
2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13130
Abstract: In June 2015, the Thai Rheumatism Association (TRA) approved an update of its recommendation for the use of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic (tsDMARD) in the treatment of rheumatoid arthritis (RA) to… read more here.
Keywords: use biologic; rheumatism association; thai rheumatism; modifying anti ... See more keywords